Clinical Trials Logo

Clinical Trial Summary

In France the prevalence of pre-lingual deafness is between 1 and 1.4 per 1000 habitants, and according to very conservative estimates, about 44 000 deaf persons use the sign language. Additionally, the prevalence of dementia in France is close to 1% (850 000 dements for a total population of 65 millions). The prevalence of dementia in pre-lingual deaf adults has also been described and is between 1 and 1.4 /100 000 habitants.

The Mini Mental State Examination (MMSE) of Folstein is a test recommended to perform the cognitive evaluation for the detection of mental disorders including dementia, and a consensual French version exists prepared by GRECO (Group of Research and Cognitive Assessments). However, to date, there are no simple, rapid and validated screening tests to study cognitive disorders in deaf persons who use the sign language. The only tests available allow a late diagnosis avoiding an optimal treatment of the patients.


Clinical Trial Description

The objective of this study is to assess the intrinsic quality of the tool MMS-LS, a mini-mental state examination that has been adapted to the sign language in order to monitor cognitive disorders in deaf people who speak sign language. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02005679
Study type Interventional
Source Lille Catholic University
Contact
Status Completed
Phase N/A
Start date June 17, 2011
Completion date December 7, 2017

See also
  Status Clinical Trial Phase
Completed NCT02007564 - Legacy Intervention Family Enactment (LIFE) N/A
Completed NCT00276510 - A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints Phase 4